New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

about

Discovery of LHRH and development of LHRH analogs for prostate cancer treatment.Inhibition of the Wnt/β-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate cancer.

P2860

Q39267156-B1AA0434-9D8F-4A62-B7AF-2EF1C6B6385C Q53691090-7D0E7132-A7D1-4A15-B250-7961B89D624D

P2860

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

Item

http://www.wikidata.org/entity/Q36748502

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

New therapies for relapsed cas ...... logs of hypothalamic hormones.

@en

type

Item

label

New therapies for relapsed cas ...... logs of hypothalamic hormones.

@en

prefLabel

New therapies for relapsed cas ...... logs of hypothalamic hormones.

@en

P1476

New therapies for relapsed cas ...... logs of hypothalamic hormones.

@en

P2093

Ferenc G Rick

http://www.w3.org/2001/XMLSchema#string

Norman L Block

http://www.w3.org/2001/XMLSchema#string

P2860

Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500-1000 times more potent

Metabolic complications of androgen deprivation therapy for prostate cancer

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

Isolation and sequencing of cDNAs for splice variants of growth hormone-releasing hormone receptors from human cancers.

Abiraterone and increased survival in metastatic prostate cancer

Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.

Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.

Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis.

Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone

Targeted cytotoxic analog of luteinizing hormone-releasing hormone (LHRH), AEZS-108 (AN-152), inhibits the growth of DU-145 human castration-resistant prostate cancer in vivo and in vitro through elevating p21 and ROS levels.

P304

925-928

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/1008-682X.152819

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Andrew Schally

P577

2015-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26112478

http://www.w3.org/2001/XMLSchema#string

P932

4814950

http://www.w3.org/2001/XMLSchema#string

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

about

P2860

P2860

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932